血清肿瘤标志物联合检测的评价

The clinical evaluation of combined tumor markers mensuration in serum

目的:回顾性研究肿瘤标志物Ca125、AFP、CEA、Ca15-3、Ca19-9、NSE,CYFRA21-1及Ca72-4在确诊恶性肿瘤中的阳性率及联合检测的辅助诊断价值.方法:肿瘤标志物测定采用电化学发光法,应用ROCHE公司生产的E170型全自动电化学发光分析仪.结果:回顾分析妇科恶性肿瘤(n＝50),肝恶性肿瘤(n=263),其它消化系统恶性肿瘤(n=252)和肺部恶性肿瘤(n=294)患者的血清肿瘤标志物检测结果,发现联合检测不同肿瘤标志物可提高阳性率.以2～4项为佳,与8项肿瘤标志物联合检测的阳性率水平基本接近.结论:适当联合检测肿瘤标志物对提高所观察恶性肿瘤的阳性率有一定价值,各肿瘤标志物间有明显的互补性,但无明显组织特异性.

Objective：To investigate the positive rates in pathologically diagnosed malignant tumor, and their accessorial value of all tumour markers mensuration together. Methods：Electrocbemiluminescence （ECL） technology and E170 automatic analyzer were used in the experiment procedures. Results：The retrospective statistic data indicated： The positive rates increased in different. tumor markers mensuration together. Two or four tests combination is good. Its positive rates was close to eight tests combination mensuration together. Conclusion：A certain value had been observed in different system malignant tumor markers which eight tumor markers mensurated together. They supplement each other. But the best and least tumor markers combination which aim at different tumour should be find in the same time. It may be more economic, and improved estimation rates evidently.